medicines patent pool

GANFEBOROLE

TUBERCULOSIS

GSK

DISEASE BURDEN

In 2021, an estimated 10.6 million people fell ill with TB worldwide, of which 450 000 incident cases of rifampicin-resistant or multidrug-resistant TB. About 1.5 million people die from TB each year. Most of the people who fall ill with TB live in LMICs.

CLINICAL RELEVANCE

Ganferobole is a Leucyl-tRNA synthetase inhibitor and it is not approved yet. Safety and efficacy data are still not mature.

INTELLECTUAL PROPERTY LANDSCAPE

Ganfeborole primary patents have been filed or granted in several LMICs and are expected to expire between 2031-2036. Secondary patents may be filed.

SERVICE DELIVERY ENABLERS

Ganfeborole is being investigated for use as part of an oral TB treatment. Companion drugs may include bedaquiline and delamanid, which are available as generics, although still not widely accessible.

REGULATORY

The product does not have regulatory approval yet and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.

MANUFACTURING

There is currently no adequate data to assess manufacturing complexity

MARKET

This medicine is still in the R&D pipeline and therefore little is known about its potential positioning in treatment protocols, pricing, and overall access plans.